Podcast Episodes
Back to Search
Ep. 326 - Market Outlook, Biosecure Returns, Biotech M&A
Season 6 Episode 326
Biotech’s fourth quarter began with a familiar feeling, with indicators pointing toward an improving public market even as political and regulatory u…
10 months, 3 weeks ago
Ep. 325 - Pfizer MFN Deal, New Trial Paradigm & Billion $ Fund
Season 6 Episode 325
The short-term consequences for Pfizer from its “most favored nation” drug pricing deal with the White House are negligible, but the long-term effect…
11 months ago
Ep. 324 - Genmab, GSK and Drug Pricing
Season 6 Episode 324
Genmab's $8 billion acquisition of multispecifics company Merus is the Danish biotech’s largest step toward marketing its own pipeline. On the latest…
11 months, 1 week ago
Ep. 323 - Agentic AI: From New Targets to the Clinic
Season 6 Episode 323
AI is bringing sweeping changes to drug development, from how targets are discovered to optimizing clinical trials to maximize an asset’s chance for …
11 months, 2 weeks ago
Ep. 322 - Takeaways from BioCentury Grand Rounds Europe
Season 6 Episode 322
Is this the U.K.’s moment to capitalize on its biotech ecosystem? That was one of the primary themes discussed at the debut Grand Rounds — Europe con…
11 months, 2 weeks ago
Ep. 321 - Pfizer’s Obesity Play & U.K. in Focus
Season 6 Episode 321
A takeout that could be worth as much as $7.3 billion has Pfizer back in the obesity drug development race. On the latest BioCentury This Week podcas…
11 months, 2 weeks ago
Ep. 320 - U.K. Biotech, U.S.-China, Insmed
Season 6 Episode 320
Merck's announcement that it is moving its R&D out of the U.K. highlights concerns about the country’s life sciences policies. On the latest BioCentu…
11 months, 3 weeks ago
Ep. 319 - David Baltimore’s Legacy, Atlas Fund, MASH Pipeline and more
Season 6 Episode 319
Molecular biologist and Nobel Prize winner David Baltimore made foundational contributions to the biopharma industry and was the essential figure beh…
1 year ago
Ep. 318 - Newco Takes on CV Risk. Plus: Disrupting Vaccines
Season 6 Episode 318
Two veteran biotech leaders are launching a new company with ambitions in the cardiovascular disease space. On the latest BioCentury This Week podcas…
1 year ago
Ep. 317 - Biotech IPOs, FDA-Stealth & Patent Threat
Season 6 Episode 317
There’s been a rare IPO filing on NASDAQ as LB Pharma looks to test the market during a year that has seen little activity among U.S. biotechs even a…
1 year ago